Skip to main content

Table 4 Treatment-emergent adverse events* during 24 months of miglustat therapy (all-enrolled population)

From: Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study

Adverse event Incidence (N = 42)
  n %
Diarrhea 31 31 (74)
Flatulence 21 21 (50)
Tremor 15 15 (36)
Headache 9 9 (21)
Paresthesia 9 9 (21)
Fatigue 8 8 (19)
Dizziness 7 7 (17)
Arthralgia 6 6 (14)
Weight decreased 6 6 (14)
Abdominal discomfort 5 5 (12)
Hypoesthesia 5 5 (12)
  1. *Adverse events with ≥10% incidence.